Connect with us

Science

Trading Penny Stocks This Summer? Here’s 4 You Don’t Want to Miss

4 penny stocks that investors are watching in Summer 2021
The post Trading Penny Stocks This Summer? Here’s 4 You Don’t Want to Miss appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Published

on

4 Penny Stocks to Buy [Or Sell] in Summer 2021

Trading penny stocks is all about having a strategy. A large part of this strategy is knowing what type of investor you are. Are you looking for short term penny stocks to buy? Or, are you more interested in finding long term value? 

These questions alone can help to greatly narrow down your watchlist. And with thousands of penny stocks out there, having a concise list will be a major benefit. The next thing to consider is all of the information regarding a specific company. This can be broken down into two categories: speculation and fundamentals. 

On one hand, speculation is all the outside factors that can make a penny stock move. This could be anything from current events and industry wide trends, to company-specific news and even rumors. Because penny stocks are all under $5, they typically have high volume. This results in extremely swift price moves, and thus, a high degree of speculation. Most investors believe that speculation is one of the largest impacting factors on a penny stocks price. 

[Read More] Energy Penny Stocks Are On The Rise; 3 to Watch Under $3

On the other hand we have fundamentals. This is the financial and factual information about a company. Typically this is all laid out in a company’s quarterly balance sheet. However, updates on a financial situation can be given out at other times as well. Interestingly enough, fundamentals can lead to speculation.

Both of these categories are very important, and its pertinent to understand how each will affect a stocks price. Considering all of this, let’s take a look at four penny stocks you don’t want to miss in Summer 2021. 

4 Penny Stocks to Watch in Summer 2021

  1. Jaguar Health Inc. (NASDAQ: JAGX)
  2. Sonim Technologies Inc. (NASDAQ: SONM)
  3. Color Star Technology Co. Ltd. (NASDAQ: CSCW)
  4. Clear Channel Outdoor Holdings Inc. (NYSE: CCO)

1. Jaguar Health Inc. (NASDAQ: JAGX)

The first company on this list is the biotech penny stock, Jaguar Health Inc. This company focuses on developing prescription medication for humans and animals. Its products are geared toward GI distress and chronic debilitating diarrhea.

Its subsidiary Napo Pharmaceuticals Inc. is developing and commercializing plant based human gastrointestinal pharmaceuticals. The company’s flagship product is known as Mytesi, which is a tablet for the relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

There are a few recent updates that are causing JAGX stock price to go up. On May 20th Jaguar and Napo provided key findings from a cancer-related diarrhea abstract that was submitted to the American Society of Clinical Oncology for a poster presentation. On June 1st the company announced initial funding of $10.8 million into Dragon SPAC.

“We’re thrilled to provide the initial funding of US$10.8 million into Dragon SPAC using funds from the recent registered direct offering – which closed on May 3, 2021 – by Jaguar to certain North American institutional investors into Jaguar.”

The founder, president and CEO of Jaguar, Lisa Conte

With all of this recent information to note, will you add JAGX to your list of penny stocks to watch?

2. Sonim Technologies Inc. (NASDAQ: SONM)

Sonim Technologies Inc. is a tech penny stock that is performing well right now. This company sells ruggedized mobile phones and accessories for those working in the field. Its mobile phones such as the Sonim XP8, XP5s, and XP3 are all based on the Android platform, and are made to be almost indestructasble. These phones can attach to public and private wireless networks and utilize a range of industrial grade accessories. Additionally, Sonim provides scanner and communications products as well.

Back in May the SONM announced a partnership with Business Mobility Partners, which is an authorized distributor of ‘T-Mobile For Business’ products and services. The goal with this is to deliver products to markets such as transportation, healthcare, logistics, construction, and more. The President of BMP said, “We are honored to create the first of its kind joint partnership between Sonim and BMP that will deliver top-of-the-line ruggedized devices to T-Mobile business and government customers.” 

This partnership could be a major benefit to both Sonim and the customers that will end up using these products. Since this information was released, SONM stock has increased in price. In the past five days alone, shares of SONM have pushed up by as much as 33%. On June 9th, this puts its share price at around $0.66 as of EOD. Considering this, will Sonim Technologies make your watchlist in June?

Penny_Stocks_to_Watch_Sonim_Technologies_Inc_SONM_Stock_Chart

3. Color Star Technology Co. Ltd. (NASDAQ: CSCW)

If you are a frequent reader of pennystocks.com, then you likely have heard of Color Star Technology Co. Ltd. If you are not familiar, let’s get you up to speed. Color Star is an entertainment penny stock that provides online and offline music education services. These services are are in use in both the United States and China. Its Color World cultural entertainment platform provides celebrity concert videos, celebrity lectures, and other unique content offerings. 

[Read More] 3 Former Penny Stocks On Robinhood To Watch Joining The Russell 2000

Currently Color Star currently has a strategic partnership with Yinmiao Culture Development Co. Ltd. to collaborate in the area of festival coordination and piano competition. On June 9th the company released a new update. Color Star announced that it will be added to the Russell Microcap Index at the end of the 2021 Russell indexes’ annual reconstitution. This will go into effect on June 25th, based on a preliminary list of additions made public on June 4th.

“Inclusion in the Russell Microcap Index® is an important achievement for Color Star. It is a testament to the significant progress we’ve made as a company. We believe that the membership in the Russel Microcap Index will provide our shares with further visibility within the financial community and greater liquidity.”

Co-CEO of Color Star Basil Wilson

Following this announcement, shares of CSCW are up substantially. Considering this, is CSCW worth adding to your penny stocks watchlist?

Penny_Stocks_to_Watch_Color_Star_Technology_Co_Ltd_CSCW_Stock_Chart

4. Clear Channel Outdoor Holdings Inc. (NYSE: CCO)

Another communications penny stock that has been performing well is Clear Channel Outdoor Holdings Inc. Clear Channel sells advertising space throughout the United States. Generally, it owns and operates these advertising displays as well. If you have driven past a billboard on the freeway, look a little bit closer and you may see Clear Channel’s name and logo in small print under the billboard. This is indicative of just how large CCOs reach is.

Clear Channel Outdoor recently launched a billboard campaign in collaboration with Operation HOPE to support the ‘1MBB’ initiative. 1MBB is an initiative to build one million black businesses by giving tools and guidance to new business owners and current business owners. 

The Vice President of Public Affairs at Clear Channel Outdoor-Los Angeles, Layne Lawson said, “We recognize the importance of spreading the message on critical initiatives like the one Operation HOPE is spearheading and we are honored to provide the resources needed to do just this.” 

In other news the company just participated in the Cowen Technology, Media, and Telecom Conference on June 3rd. On May 17th the company announced the pricing of an offering of $1.05 billion aggregate principal amount of 7.500% senior notes due 2029.

The goal with these funds is to redeem its subsidiary, Clear Channel Worldwide Holdings Inc’s outstanding $961,525,000 senior notes due 2024. This should help to push better numbers on its next balance sheet. With all of this info to note, is CCO on your list of penny stocks to watch this month?

Penny_Stocks_to_Watch_Clear_Channel_Outdoor_Holdings_Inc_CCO_Stock

Which Penny Stocks Are You Watching Right Now?

As we move closer into the second half of 2021, penny stocks are heating up. We see this via the large volume in the stock market right now alongside the big daily gains with certain penny stocks.

[Read More] Hot Penny Stocks To Watch As AMC Stock Ignites Small Caps In June

While finding the best penny stocks to buy can be challenging, making a watchlist and researching the companies within it, will always help in the long run. Considering the excitement surrounding the post-pandemic economy, many investors are hopeful about the future. With all of this in mind, which penny stocks are you watching right now?

The post Trading Penny Stocks This Summer? Here’s 4 You Don’t Want to Miss appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Spread & Containment

AstraZeneca antibody cocktail fails to prevent Covid-19 symptoms in large trial

AstraZeneca said a late-stage trial failed to provide evidence that the company’s Covid-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.

Published

on

Astra antibody cocktail fails to prevent COVID-19 symptoms in large trial

(Reuters; )

June 15 (Reuters) – AstraZeneca (AZN.L) said on Tuesday a late-stage trial failed to provide evidence that its COVID-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.

The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing COVID-19 symptoms.

The therapy, AZD7442, was 33% effective in reducing the risk of people developing symptoms compared with a placebo, but that result was not statistically significant — meaning it might have been due to chance and not the therapy.

The Phase III study, which has not been peer reviewed, included 1,121 participants in the United Kingdom and the United States. The vast majority, though not all, were free of the virus at the start of the trial.

Results for a subset of participants who were not infected to begin with was more encouraging but the primary analysis rested on results from all participants.

FILE PHOTO: A computer image created by Nexu Science Communication together with Trinity College in Dublin, shows a model structurally representative of a betacoronavirus which is the type of virus linked to COVID-19, better known as the coronavirus linked to the Wuhan outbreak, shared with Reuters on February 18, 2020. NEXU Science Communication/via REUTERS

“While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442,” AstraZeneca Executive Vice President Mene Pangalos said in a statement.

The company is banking on further studies to revive the product’s fortunes. Five more trials are ongoing, testing the antibody cocktail as treatment or in prevention.

The next one will likely be from a larger trial testing the product in people with a weakened immune system due to cancer or an organ transplant, who may not benefit from a vaccine.

TARGETED ALTERNATIVES

AZD7442 belongs to a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the body to fight off infections.

Similar therapies developed by rivals Regeneron (REGN.O) and Eli Lilly (LLY.N) have been approved by U.S. regulators for treating unhospitalised COVID patients.

European regulators have also authorised Regeneron’s therapy and are reviewing those developed by partners GlaxoSmithKline (GSK.L) and Vir Biotechnology (VIR.O) as well as by Lilly and Celltrion (068270.KS).

Regeneron is also seeking U.S. authorisation for its therapy as a preventative treatment.

But the AstraZeneca results are a small blow for the drug industry as it tries to find more targeted alternatives to COVID-19 inoculations, particularly for people who may not be able to get vaccinated or those who may have an inadequate response to inoculations.

The Anglo-Swedish drugmaker, which has faced a rollercoaster of challenges with the rollout of its COVID-19 vaccine, is also developing new treatments and repurposing existing drugs to fight the virus.

AstraZeneca also said on Tuesday it was in talks with the U.S. government on “next steps” regarding a $205 million deal to supply up to 500,000 doses of AZD7442. Swiss manufacturer Lonza (LONN.S) was contracted to produce AZD7442.

Shares in the company were largely unchanged on the London Stock Exchange.

The full results will be submitted for publication in a peer-reviewed medical journal, the company said.

Reporting by Vishwadha Chander in Bengaluru; Editing by Shounak Dasgupta

Our Standards: The Thomson Reuters Trust Principles.

 

Reuters source:

https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-says-its-antibody-treatment-failed-in-preventing-covid-19-exposed-2021-06-15

 

Read More

Continue Reading

Government

Former FDA Head Takes on Exec Role at Flagship’s Preemptive Health Initiative

Stephen Hahn, the Commissioner of the U.S. Food and Drug Administration under former President Donald Trump, took on a new role as chief medical officer of a new health security initiative launched by Flagship Pioneering, a life sciences venture firm…

Published

on

Former FDA Head Takes on Exec Role at Flagship’s Preemptive Health Initiative

 

Stephen Hahn, the Commissioner of the U.S. Food and Drug Administration (FDA) under former President Donald Trump, has taken on a new role as chief medical officer of a new health security initiative launched by Flagship Pioneering, a life sciences venture firm that incubates and curates biopharma companies.

First announced Monday, Flagship’s Preemptive Medicine and Health Security initiative aimed at developing products that can help people before they get sick. This division will focus on infectious disease threats and pursue bold treatments for existing diseases, including cancer, obesity, and neurodegeneration. 

In a brief statement, Hahn, who served as commissioner from December 2019 until January 2021, said the importance of investing in innovation and preemptive medications has never been more apparent. 

“In my career I have been a doctor and a researcher foremost and it is an honor to join Flagship Pioneering in its efforts to prioritize innovation, particularly in its Preemptive Medicine and Health Security Initiative. The more we can embrace a “what if …” approach the better we can support and protect the health and well-being of people here in the U.S. and around the world,” Hahn said in a statement. 

During his time at the FDA, Hahn was at the forefront of the government’s effort to battle the COVID-19 pandemic. His office oversaw the regulatory authorization of antivirals, antibody therapeutics and vaccines, as well as diagnostics and other tools to battle the novel coronavirus. 

Kevin Dietsch-Pool/Getty Images

Hahn bore the brunt of verbal barbs aimed at the FDA by the former president for not rushing to authorize a vaccine for COVID-19 ahead of the November 2020 election. The second vaccine authorized by the FDA for COVID-19 was developed by Moderna, a Flagship company. 

Prior to his confirmation as FDA Commissioner, Hahn, a well-respected oncologist, served as chief medical executive of the vaunted The University of Texas MD Anderson Cancer Center. Hahn was named deputy president and chief operating officer in 2017. In that role, he was responsible for the day-to-day operations of the cancer center, which includes managing more than 21,000 employees and a $5.2 billion operating budget. He was promoted to that position two years after joining MD Anderson as division head, department chair and professor of Radiation Oncology. Prior to MD Anderson, Hahn served as head of the radiation oncology department at the University of Pennsylvania’s Perelman School of Medicine.

Flagship Founder and Chief Executive Officer Noubar Afeyan said the COVID-19 pandemic that shut down economies and caused the deaths of more than 3.8 million people across the world was an important reminder that health security is a top global priority. In addition, the ongoing pandemic brings into “stark focus” the importance of preemptive medications. 

Hahn, who helmed the FDA for three years and before that served as chief medical executive at The University of Texas MD Anderson Cancer Center, has extensive experience overseeing clinical and administrative programs. Afeyan said the new division would benefit from Hahn’s experience as FDA Commissioner and help steer the Preemptive Medicine and Health Security initiative as it explores Flagship’s “growing number of explorations and companies in this emerging field.”

It is not unusual for former FDA heads to take prominent roles with companies. For example, former FDA Commissioner Scott Gottlieb, Trump’s first FDA Commissioner, took a position on the Pfizer Board of Directors weeks after departing his government role. He has also taken positions on other boards since then, including Aetion, FasterCures and Illumina.

 

BioSpace source:

https://www.biospace.com/article/former-fda-head-stephen-hahn-takes-cmo-role-at-flagship-pioneering-preemptive-health-initiative-

 

Read More

Continue Reading

Government

Five U.S. states had coronavirus infections even before first reported cases – study

At least seven people in five U.S. states were infected with the novel coronavirus weeks before those states reported their first cases, a new government study showed.

Published

on

Five U.S. states had coronavirus infections even before first reported cases – study

(Reuters) – At least seven people in five U.S. states were infected with the novel coronavirus weeks before those states reported their first cases, a new government study showed.

Participants who reported antibodies against SARS-CoV-2 were likely exposed to the virus at least several weeks before their sample was taken, as the antibodies do not appear until about two weeks after a person has been infected, the researchers said.

The latest results build on findings from a Centers for Disease Control and Prevention study that suggested the novel coronavirus may have been circulating in the United States last December, well before the first COVID-19 case was diagnosed on Jan. 19, 2020.

A protective face mask lays, as the global outbreak of the coronavirus disease (COVID-19) continues, beside leaves at the lakefront in Chicago, Illinois, U.S., December 6, 2020. REUTERS/Shannon/File Photo

The positive samples came from Illinois, Massachusetts, Mississippi, Pennsylvania and Wisconsin, and were part of a study of more than 24,000 blood samples taken for a National Institutes of Health research program between Jan. 2 and March 18, 2020.

Samples from participants in Illinois were collected on Jan. 7 and Massachusetts on Jan. 8, suggesting that the virus was present in those states as early as late December.

“This study allows us to uncover more information about the beginning of the U.S. epidemic,” said Josh Denny, one of the study authors.

The findings were published in the journal Clinical Infectious Diseases.

Reporting by Mrinalika Roy in Bengaluru; Editing by Anil D’Silva

Our Standards: The Thomson Reuters Trust Principles.

 

Reuters source:

https://www.reuters.com/business/healthcare-pharmaceuticals/five-us-states-had-coronavirus-infections-even-before-first-reported-cases-study-2021-06-15

 

Read More

Continue Reading

Trending